{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T12:33:24Z","timestamp":1774528404015,"version":"3.50.1"},"reference-count":112,"publisher":"Oxford University Press (OUP)","issue":"19","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,10,1]]},"DOI":"10.2146\/ajhp100637","type":"journal-article","created":{"date-parts":[[2011,9,19]],"date-time":"2011-09-19T18:49:15Z","timestamp":1316458155000},"page":"1791-1804","source":"Crossref","is-referenced-by-count":26,"title":["Drug-induced heart failure"],"prefix":"10.1093","volume":"68","author":[{"given":"Carleton B.","family":"Maxwell","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Carolinas Medical Center, Charlotte, NC."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoine T.","family":"Jenkins","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Chicago State University, Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"key\n\t\t\t\t2019041106041248800_b1-0681791","first-page":"e154","article-title":"ACC\/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult. A report of the American College of Cardiology\/American Heart Association task force on practice guidelines (writing committee to update the 2001 guidelines for the evaluation and management of heart failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society","volume":"112","author":"Hunt","year":"2005","journal-title":"Circulation."},{"key":"key\n\t\t\t\t2019041106041248800_b2-0681791","first-page":"e391","article-title":"2009 focused update incorporated into the ACC\/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation","volume":"119","author":"Hunt","year":"2009","journal-title":"Circulation."},{"key":"key\n\t\t\t\t2019041106041248800_b3-0681791","first-page":"e46","article-title":"Heart disease and stroke statistics\u2014 2010 update: a report from the American Heart Association","volume":"121","author":"Lloyd-Jones","year":"2010","journal-title":"Circulation."},{"key":"key\n\t\t\t\t2019041106041248800_b4-0681791","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cardfail.2005.11.005","article-title":"HFSA 2006 comprehensive heart failure practice guideline","volume":"12","author":"Adams","year":"2006","journal-title":"J Card Fail."},{"key":"key\n\t\t\t\t2019041106041248800_b5-0681791","first-page":"1977","article-title":"Writing on behalf of the 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult Writing Committee. 2009 focused update: ACCF\/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation\/American Heart Association task force on practice guidelines","volume":"119","author":"Jessup","year":"2009","journal-title":"Circulation."},{"key":"key\n\t\t\t\t2019041106041248800_b6-0681791","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1001\/jama.1979.03290450033020","article-title":"Diabetes and cardiovascular disease: the Framingham Study","volume":"241","author":"Kannel","year":"1979","journal-title":"JAMA."},{"key":"key\n\t\t\t\t2019041106041248800_b7-0681791","doi-asserted-by":"crossref","first-page":"154","DOI":"10.2337\/diacare.29.01.06.dc05-0711","article-title":"Thiazolidinediones: the case for early use","volume":"29","author":"Kendall","year":"2006","journal-title":"Diabetes Care."},{"key":"key\n\t\t\t\t2019041106041248800_b8-0681791","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/CRD.0b013e31819faab2","article-title":"Thiazolidinediones and congestive heart failure","volume":"17","author":"Patel","year":"2009","journal-title":"Cardiol Rev."},{"key":"key\n\t\t\t\t2019041106041248800_b9-0681791","volume-title":"Avandia (rosiglitazone malate) package insert","year":"2009"},{"key":"key\n\t\t\t\t2019041106041248800_b10-0681791","volume-title":"Actos (pioglitazone hydrochloride) package insert","year":"2008"},{"key":"key\n\t\t\t\t2019041106041248800_b11-0681791","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1161\/01.CIR.0000103683.99399.7E","article-title":"Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from American Heart Association and American Diabetes Association","volume":"108","author":"Nesto","year":"2003","journal-title":"Circulation."},{"key":"key\n\t\t\t\t2019041106041248800_b12-0681791","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1345\/aph.1D400","article-title":"Thiazolidinedione-induced congestive heart failure","volume":"38","author":"Cheng","year":"2004","journal-title":"Ann Pharmacother."},{"key":"key\n\t\t\t\t2019041106041248800_b13-0681791","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.2337\/diacare.26.11.2983","article-title":"Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes","volume":"26","author":"Delea","year":"2003","journal-title":"Diabetes Care."},{"key":"key\n\t\t\t\t2019041106041248800_b14-0681791","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone clinical trial in macro Vascular Events): a randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet."},{"key":"key\n\t\t\t\t2019041106041248800_b15-0681791","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/S0140-6736(06)69420-8","article-title":"Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial","volume":"368","author":"DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) trial investigators","year":"2006","journal-title":"Lancet."},{"key":"key\n\t\t\t\t2019041106041248800_b16-0681791","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","author":"Nissen","year":"2007","journal-title":"N Engl J Med."},{"key":"key\n\t\t\t\t2019041106041248800_b17-0681791","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1056\/NEJMoa073394","article-title":"Rosiglitazone evaluated for cardiovascular outcomes\u2014an interim analysis","volume":"357","author":"Horne","year":"2007","journal-title":"N Engl J Med."},{"key":"key\n\t\t\t\t2019041106041248800_b18-0681791","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.2337\/dc07-0141","article-title":"Thiazolidinediones and heart failure: a teleo-analysis","volume":"30","author":"Singh","year":"2007","journal-title":"Diabetes Care."},{"key":"key\n\t\t\t\t2019041106041248800_b19-0681791","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1001\/archinte.168.21.2368","article-title":"Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy","volume":"168","author":"Winkelmayer","year":"2008","journal-title":"Arch Intern Med."},{"key":"key\n\t\t\t\t2019041106041248800_b20-0681791","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1001\/jama.2010.920","article-title":"Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone","volume":"304","author":"Graham","year":"2010","journal-title":"JAMA."},{"key":"key\n\t\t\t\t2019041106041248800_b21-0681791","unstructured":"Food and Drug Administration. FDA drug safety communication: updated risk evaluation and mitigation strategy (REMS) to restrict access to rosiglitazone-containing medicines including Avandia, Avandamet, and Avandaryl. www.fda.gov\/drugs\/drugsafety\/ucm255005.htm (accessed 2011 Jun 21)."},{"key":"key\n\t\t\t\t2019041106041248800_b22-0681791","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2165\/00002018-200022040-00002","article-title":"Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention","volume":"22","author":"Pai","year":"2000","journal-title":"Drug Saf."},{"key":"key\n\t\t\t\t2019041106041248800_b23-0681791","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S1040-8428(97)10007-5","article-title":"Anthracycline-induced cardiotoxicity in children and young adults","volume":"27","author":"Giantris","year":"1998","journal-title":"Crit Rev Oncol Hematol."},{"key":"key\n\t\t\t\t2019041106041248800_b24-0681791","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/1097-0142(197308)32:2<302::AID-CNCR2820320205>3.0.CO;2-2","article-title":"A clinicopathologic analysis of adriamycin cardiotoxicity","volume":"32","author":"Lefrak","year":"1973","journal-title":"Cancer."},{"key":"key\n\t\t\t\t2019041106041248800_b25-0681791","doi-asserted-by":"crossref","first-page":"3502","DOI":"10.1200\/JCO.1998.16.11.3502","article-title":"Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer","volume":"16","author":"Ryberg","year":"1998","journal-title":"J Clin Oncol."},{"key":"key\n\t\t\t\t2019041106041248800_b26-0681791","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/cncr.11407","article-title":"Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials","volume":"97","author":"Swain","year":"2003","journal-title":"Cancer."},{"key":"key\n\t\t\t\t2019041106041248800_b27-0681791","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1161\/01.CIR.0000133187.74800.B9","article-title":"Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management","volume":"109","author":"Yeh","year":"2004","journal-title":"Circulation."},{"key":"key\n\t\t\t\t2019041106041248800_b28-0681791","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.pharmthera.2009.10.002","article-title":"Anticancer drugs and cardiotoxicity: insights and perspectives in the era of targeted therapy","volume":"125","author":"Raschi","year":"2010","journal-title":"Pharmacol Ther."},{"key":"key\n\t\t\t\t2019041106041248800_b29-0681791","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/BF00174159","article-title":"Mitoxantrone: an overview of safety and toxicity","volume":"3","author":"Posner","year":"1985","journal-title":"Invest New Drugs."},{"key":"key\n\t\t\t\t2019041106041248800_b30-0681791","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1124\/pr.56.2.6","article-title":"Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity","volume":"56","author":"Minotti","year":"2004","journal-title":"Pharmacol Rev."},{"key":"key\n\t\t\t\t2019041106041248800_b31-0681791","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1001\/archinte.1981.00340060066015","article-title":"Cardiotoxicity associated with high-dose cyclophosphamide therapy","volume":"141","author":"Gottdiener","year":"1981","journal-title":"Arch Intern Med."},{"key":"key\n\t\t\t\t2019041106041248800_b32-0681791","first-page":"91","article-title":"Cardiac involvement in bone marrow transplantation: electrocardiographic changes, arrhythmias, heart failure and autopsy findings","volume":"5","author":"Kupari","year":"1990","journal-title":"Bone Marrow Transplant."},{"key":"key\n\t\t\t\t2019041106041248800_b33-0681791","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1200\/JCO.1991.9.7.1215","article-title":"Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens","volume":"9","author":"Braverman","year":"1991","journal-title":"J Clin Oncol."},{"issue":"(1, suppl 3)","key":"key\n\t\t\t\t2019041106041248800_b34-0681791","first-page":"2","article-title":"Ifosfamide\u2014pharmacologic overview","volume":"16","author":"Sarosy","year":"1989","journal-title":"Semin Oncol."},{"key":"key\n\t\t\t\t2019041106041248800_b35-0681791","doi-asserted-by":"crossref","first-page":"31","DOI":"10.7326\/0003-4819-118-1-199301010-00006","article-title":"High-dose ifosfamide is associated with severe, reversible cardiac dysfunction","volume":"118","author":"Quezado","year":"1993","journal-title":"Ann Intern Med."},{"key":"key\n\t\t\t\t2019041106041248800_b36-0681791","first-page":"1005","article-title":"Adriamycin and mitomycin C: possible synergistic cardiotoxicity","volume":"62","author":"Buzdar","year":"1978","journal-title":"Cancer Treat Rep."},{"key":"key\n\t\t\t\t2019041106041248800_b37-0681791","doi-asserted-by":"crossref","first-page":"783","DOI":"10.2165\/00002018-200730090-00005","article-title":"Drug-induced cardiovascular disorders","volume":"30","author":"Murphy","year":"2007","journal-title":"Drug Saf."},{"key":"key\n\t\t\t\t2019041106041248800_b38-0681791","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMra043186","article-title":"Trastuzumab\u2014mechanism of action and use in clinical practice","volume":"357","author":"Hudis","year":"2007","journal-title":"N Engl J Med."},{"key":"key\n\t\t\t\t2019041106041248800_b39-0681791","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.cardfail.2009.04.011","article-title":"Trastuzumab-induced cardiomyopathy: not as benign as it looks? A retrospective study","volume":"15","author":"Guglin","year":"2009","journal-title":"J Card Fail."},{"key":"key\n\t\t\t\t2019041106041248800_b40-0681791","doi-asserted-by":"crossref","first-page":"7820","DOI":"10.1200\/JCO.2005.13.300","article-title":"Reversibility of trastuzumab-related cardiomyopathy: new insights based on clinical course and response to medical treatment","volume":"23","author":"Ewer","year":"2005","journal-title":"J Clin Oncol."},{"key":"key\n\t\t\t\t2019041106041248800_b41-0681791","volume-title":"Herceptin (trastuzumab) package insert","year":"2010"},{"key":"key\n\t\t\t\t2019041106041248800_b42-0681791","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0025-6196(11)60896-3","article-title":"Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials","volume":"83","author":"Perez","year":"2008","journal-title":"Mayo Clin Proc."},{"key":"key\n\t\t\t\t2019041106041248800_b43-0681791","volume-title":"Tykerb (lapatinib) package insert","year":"2010"},{"key":"key\n\t\t\t\t2019041106041248800_b44-0681791","volume-title":"Avastin (bevacizumab) package insert","year":"2011"},{"key":"key\n\t\t\t\t2019041106041248800_b45-0681791","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1200\/JCO.2010.31.9129","article-title":"Congestive heart failure risk in patients with breast cancer treated with bevacizumab","volume":"29","author":"Choueiri","year":"2011","journal-title":"J Clin Oncol."},{"key":"key\n\t\t\t\t2019041106041248800_b46-0681791","unstructured":"Food and Drug Administration. Avastin (bevacizumab): process for removal of breast cancer indication begun. www.fda.gov\/Safety\/MedWatch\/SafetyInformation\/SafetyAlertsforHumanMedicalProducts\/ucm237280.htm (accessed 2011 May 16)."},{"key":"key\n\t\t\t\t2019041106041248800_b47-0681791","volume-title":"Sutent (sunitinib malate) package insert","year":"2010"},{"key":"key\n\t\t\t\t2019041106041248800_b48-0681791","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/S0140-6736(07)61865-0","article-title":"Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib","volume":"370","author":"Chu","year":"2007","journal-title":"Lancet."},{"key":"key\n\t\t\t\t2019041106041248800_b49-0681791","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1001\/jama.295.21.2516","article-title":"Sunitinib in patients with metastatic renal cell carcinoma","volume":"295","author":"Motzer","year":"2006","journal-title":"JAMA."},{"key":"key\n\t\t\t\t2019041106041248800_b50-0681791","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMra013339","article-title":"Imatinib mesylate\u2014a new oral targeted therapy","volume":"346","author":"Savage","year":"2002","journal-title":"N Engl J Med."},{"key":"key\n\t\t\t\t2019041106041248800_b51-0681791","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1182\/blood-2007-01-070144","article-title":"Congestive heart failure is a rare event in patients receiving imatinib therapy","volume":"110","author":"Atallah","year":"2007","journal-title":"Blood."},{"key":"key\n\t\t\t\t2019041106041248800_b52-0681791","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/cncr.24683","article-title":"Rare incidence of congestive heart failure in gastrointestinal stromal tumor and other sarcoma patients receiving imatinib mesylate","volume":"116","author":"Trent","year":"2010","journal-title":"Cancer."},{"key":"key\n\t\t\t\t2019041106041248800_b53-0681791","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1345\/aph.19344","article-title":"Treatment options for rheumatoid arthritis: celecoxib, leflunomide etanercept, and infliximab","volume":"34","author":"Luong","year":"2000","journal-title":"Ann Pharmacother."},{"key":"key\n\t\t\t\t2019041106041248800_b54-0681791","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1592\/phco.19.15.1138.30574","article-title":"Medical options for treating Crohn\u2019s disease in adults: focus on antitumor necrosis factor-\u03b1 chimeric monoclonal antibody","volume":"19","author":"Wall","year":"1999","journal-title":"Pharmacotherapy."},{"key":"key\n\t\t\t\t2019041106041248800_b55-0681791","first-page":"36","article-title":"Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis","volume":"30","author":"Wolfe","year":"2003","journal-title":"J Rheumatol."},{"key":"key\n\t\t\t\t2019041106041248800_b56-0681791","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/art.1780370408","article-title":"The mortality of rheumatoid arthritis","volume":"37","author":"Wolfe","year":"1994","journal-title":"Arthritis Rheum."},{"key":"key\n\t\t\t\t2019041106041248800_b57-0681791","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.autrev.2004.09.004","article-title":"TNF-\u03b1, rheumatoid arthritis, and heart failure: a rheumatological dilemma","volume":"4","author":"Puttini-Sarzi","year":"2005","journal-title":"Autoimmun Rev."},{"key":"key\n\t\t\t\t2019041106041248800_b58-0681791","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S1071-9164(96)80047-9","article-title":"Basic mechanisms in heart failure: the cytokine hypothesis","volume":"2","author":"Seta","year":"1996","journal-title":"J Card Fail."},{"key":"key\n\t\t\t\t2019041106041248800_b59-0681791","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0163-7258(02)00176-6","article-title":"Tumor necrosis factor-\u03b1 in cardiovascular biology and the potential role for anti-tumor necrosis factor-\u03b1 therapy in heart disease","volume":"94","author":"Sack","year":"2002","journal-title":"Pharmacol Ther."},{"key":"key\n\t\t\t\t2019041106041248800_b60-0681791","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S0735-1097(99)00600-2","article-title":"The role of tumor necrosis factor in the pathophysiology of heart failure","volume":"35","author":"Feldman","year":"2000","journal-title":"J Am Coll Cardiol."},{"key":"key\n\t\t\t\t2019041106041248800_b61-0681791","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1161\/01.RES.81.4.627","article-title":"Dilated cardiomyopathy in transgenic mice with cardiac specific overexpression of tumor necrosis factor","volume":"81","author":"Kubota","year":"1997","journal-title":"Circ Res."},{"key":"key\n\t\t\t\t2019041106041248800_b62-0681791","volume-title":"Enbrel (etanercept) package insert","year":"2010"},{"key":"key\n\t\t\t\t2019041106041248800_b63-0681791","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1161\/hc5001.101749","article-title":"Tumor necrosis factor antagonism with etanercept improves systemic endothelial vasoreactivity in patients with advanced heart failure","volume":"104","author":"Fichtlscherer","year":"2001","journal-title":"Circulation."},{"key":"key\n\t\t\t\t2019041106041248800_b64-0681791","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S1388-9842(02)00121-6","article-title":"Clinical trials update: RENEWAL (RENAISSANCE and RECOVER) and ATTACH","volume":"4","author":"Coletta","year":"2002","journal-title":"Eur J Heart Fail."},{"key":"key\n\t\t\t\t2019041106041248800_b65-0681791","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0167-5273(02)00470-9","article-title":"How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL, and ATTACH","volume":"86","author":"Anker","year":"2002","journal-title":"Int J Cardiol."},{"key":"key\n\t\t\t\t2019041106041248800_b66-0681791","volume-title":"Remicade (infliximab) package insert","year":"2010"},{"key":"key\n\t\t\t\t2019041106041248800_b67-0681791","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1093\/rheumatology\/kem212","article-title":"Heart failure among younger rheumatoid arthritis and Crohn\u2019s patients exposed to TNF-\u03b1 antagonists","volume":"46","author":"Curtis","year":"2007","journal-title":"Rheumatology."},{"key":"key\n\t\t\t\t2019041106041248800_b68-0681791","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/art.23281","article-title":"Does tumor necrosis factor \u03b1 inhibition promote or prevent heart failure in patients with rheumatoid arthritis?","volume":"58","author":"Listing","year":"2008","journal-title":"Arthritis Rheum."},{"key":"key\n\t\t\t\t2019041106041248800_b69-0681791","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/BOR.0b013e3282fb03d8","article-title":"Biologics and heart failure in rheumatoid arthritis: are we any wiser?","volume":"20","author":"Danila","year":"2008","journal-title":"Curr Opin Rheumatol."},{"key":"key\n\t\t\t\t2019041106041248800_b70-0681791","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.amjmed.2003.09.039","article-title":"Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy","volume":"116","author":"Wolfe","year":"2004","journal-title":"Am J Med."},{"key":"key\n\t\t\t\t2019041106041248800_b71-0681791","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/ki.1993.293","article-title":"Renal complications of nonsteroidal anti-inflammatory drugs","volume":"44","author":"Schlondorff","year":"1993","journal-title":"Kidney Int."},{"key":"key\n\t\t\t\t2019041106041248800_b72-0681791","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2165\/00002018-199308020-00002","article-title":"Adverse drug interactions with nonsteroidal anti-inflammatory drugs (NSAIDs): recognition, management and avoidance","volume":"8","author":"Johnson","year":"1993","journal-title":"Drug Saf."},{"key":"key\n\t\t\t\t2019041106041248800_b73-0681791","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1001\/archinte.160.6.777","article-title":"Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem","volume":"160","author":"Page","year":"2000","journal-title":"Arch Intern Med."},{"key":"key\n\t\t\t\t2019041106041248800_b74-0681791","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1001\/archinte.162.3.265","article-title":"Association of nonsteroidal anti-inflammatory drugs with first occurrence of heart failure and with relapsing heart failure: the Rotterdam Study","volume":"162","author":"Feenstra","year":"2002","journal-title":"Arch Intern Med."},{"key":"key\n\t\t\t\t2019041106041248800_b75-0681791","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/S0140-6736(04)16299-5","article-title":"Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti- inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study","volume":"363","author":"Mamdani","year":"2004","journal-title":"Lancet."},{"key":"key\n\t\t\t\t2019041106041248800_b76-0681791","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1136\/hrt.2005.082388","article-title":"Non-steroidal anti-inflammatory drugs and risk of first hospital admission for heart failure in the general population","volume":"92","author":"Huerta","year":"2006","journal-title":"Heart."},{"key":"key\n\t\t\t\t2019041106041248800_b77-0681791","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1056\/NEJM199507133330201","article-title":"Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia","volume":"333","author":"Singh","year":"1995","journal-title":"N Engl J Med."},{"key":"key\n\t\t\t\t2019041106041248800_b78-0681791","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1056\/NEJM199909163411201","article-title":"Dofetilide in patients with congestive heart failure and left ventricular dysfunction","volume":"341","author":"Torp-Pedersen","year":"1999","journal-title":"N Engl J Med."},{"key":"key\n\t\t\t\t2019041106041248800_b79-0681791","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJM198003133021106","article-title":"Congestive heart failure caused by oral disopyramide","volume":"302","author":"Podrid","year":"1980","journal-title":"N Engl J Med."},{"key":"key\n\t\t\t\t2019041106041248800_b80-0681791","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/0735-1097(89)90436-1","article-title":"Congestive heart failure induced by six of the newer antiarrhythmic drugs","volume":"14","author":"Ravid","year":"1989","journal-title":"J Am Coll Cardiol."},{"key":"key\n\t\t\t\t2019041106041248800_b81-0681791","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/S0140-6736(10)60096-7","article-title":"New antiarrhythmic drugs for treatment of atrial fibrillation","volume":"375","author":"Dobrev","year":"2010","journal-title":"Lancet."},{"key":"key\n\t\t\t\t2019041106041248800_b82-0681791","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1056\/NEJMoa0800456","article-title":"Increased mortality after drone-darone therapy for severe heart failure","volume":"358","author":"K\u00f8ber","year":"2008","journal-title":"N Engl J Med."},{"key":"key\n\t\t\t\t2019041106041248800_b83-0681791","volume-title":"Multaq (dronedarone) package insert","year":"2009"},{"key":"key\n\t\t\t\t2019041106041248800_b84-0681791","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.7326\/0003-4819-119-12-199312150-00007","article-title":"Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates","volume":"119","author":"Boumpas","year":"1993","journal-title":"Ann Intern Med."},{"key":"key\n\t\t\t\t2019041106041248800_b85-0681791","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S0002-9629(15)41701-X","article-title":"Corticosteroid usage: observations at a community hospital","volume":"311","author":"Pensabeni-Jasper","year":"1996","journal-title":"Am J Med Sci."},{"key":"key\n\t\t\t\t2019041106041248800_b86-0681791","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1136\/hrt.2003.020180","article-title":"Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study","volume":"90","author":"Souverein","year":"2004","journal-title":"Heart."},{"key":"key\n\t\t\t\t2019041106041248800_b87-0681791","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/01.fjc.0000245242.57088.5b","article-title":"Potent potentiating diuretic effects of prednisone in congestive heart failure","volume":"48","author":"Liu","year":"2006","journal-title":"J Cardiovasc Pharmacol."},{"key":"key\n\t\t\t\t2019041106041248800_b88-0681791","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S0828-282X(07)70840-1","article-title":"Potent diuretic effects of prednisone in heart failure patients with refractory diuretic resistance","volume":"23","author":"Liu","year":"2007","journal-title":"Can J Cardiol."},{"key":"key\n\t\t\t\t2019041106041248800_b89-0681791","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2165\/00129784-200303010-00004","article-title":"Defining the role of calcium channel antagonists in heart failure due to systolic dysfunction","volume":"3","author":"Mah\u00e8","year":"2003","journal-title":"Am J Cardiovasc Drugs."},{"key":"key\n\t\t\t\t2019041106041248800_b90-0681791","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1001\/jama.1992.03480140082038","article-title":"Can we alter survival in patients with congestive heart failure?","volume":"267","author":"Feldman","year":"1992","journal-title":"JAMA."},{"key":"key\n\t\t\t\t2019041106041248800_b91-0681791","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/S0735-1097(87)80135-3","article-title":"Prognostic importance of immediate hemodynamic response to nifedipine in patients with severe left ventricular dysfunction","volume":"10","author":"Packer","year":"1987","journal-title":"J Am Coll Cardiol."},{"issue":"(suppl I)","key":"key\n\t\t\t\t2019041106041248800_b92-0681791","first-page":"I8","article-title":"Sustained-release calcium channel antagonists in cardiovascular disease: pharmacology and current therapeutic use","volume":"19","author":"Silvestry","year":"1998","journal-title":"Eur Heart J."},{"key":"key\n\t\t\t\t2019041106041248800_b93-0681791","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(97)05381-6","article-title":"Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension: the Systolic Hypertension in Europe (Syst-Eur) trial investigators","volume":"350","author":"Staessen","year":"1997","journal-title":"Lancet."},{"key":"key\n\t\t\t\t2019041106041248800_b94-0681791","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S0140-6736(00)02527-7","article-title":"Morbidity and mortality in patients randomised to double blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT)","volume":"356","author":"Brown","year":"2000","journal-title":"Lancet."},{"key":"key\n\t\t\t\t2019041106041248800_b95-0681791","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"288","author":"ALLHAT officers and coordinators for the ALLHAT Collaborative Research Group","year":"2002","journal-title":"JAMA."},{"key":"key\n\t\t\t\t2019041106041248800_b96-0681791","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJM199610103351504","article-title":"Effect of amlodipine on morbidity and mortality in severe chronic heart failure","volume":"335","author":"Packer","year":"1996","journal-title":"N Engl J Med."},{"key":"key\n\t\t\t\t2019041106041248800_b97-0681791","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S1388-9842(00)00080-5","article-title":"Clinical trials update: OPTIME-CHF, PRAISE-2, ALLHAT","volume":"2","author":"Thackray","year":"2000","journal-title":"Eur J Heart Fail."},{"key":"key\n\t\t\t\t2019041106041248800_b98-0681791","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1161\/01.CIR.96.3.856","article-title":"Effect of calcium channel antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III","volume":"96","author":"Cohn","year":"1997","journal-title":"Circulation."},{"key":"key\n\t\t\t\t2019041106041248800_b99-0681791","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.cardfail.2010.04.005","article-title":"Executive summary: HFSA 2010 comprehensive heart failure practice guideline","volume":"16","author":"Lindenfeld","year":"2010","journal-title":"J Card Fail."},{"key":"key\n\t\t\t\t2019041106041248800_b100-0681791","volume-title":"Sporonox (itraconazole) package insert","year":"2009"},{"key":"key\n\t\t\t\t2019041106041248800_b101-0681791","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1016\/S0140-6736(00)04891-1","article-title":"Congestive heart failure associated with itraconazole","volume":"357","author":"Ahmad","year":"2001","journal-title":"Lancet."},{"key":"key\n\t\t\t\t2019041106041248800_b102-0681791","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1183\/09031936.00021208","article-title":"Cardiovascular adverse effects during itraconazole therapy","volume":"32","author":"Fung","year":"2008","journal-title":"Eur Respir J."},{"key":"key\n\t\t\t\t2019041106041248800_b103-0681791","doi-asserted-by":"crossref","first-page":"567","DOI":"10.2165\/00002018-200629070-00003","article-title":"Heart failure induced by non-cardiac drugs","volume":"29","author":"Sl\u00f8rdal","year":"2006","journal-title":"Drug Saf."},{"key":"key\n\t\t\t\t2019041106041248800_b104-0681791","unstructured":"Food and Drug Administration. Fenphen safety update information. www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm072820.htm (accessed 2011 May 17)."},{"key":"key\n\t\t\t\t2019041106041248800_b105-0681791","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/00000441-200104000-00008","article-title":"Appetite suppressants and valvular heart disease","volume":"321","author":"Weissman","year":"2001","journal-title":"Am J Med Sci."},{"key":"key\n\t\t\t\t2019041106041248800_b106-0681791","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1161\/01.CIR.101.17.2071","article-title":"Fenfluramine and phentermine and cardiovascular findings: effects of treatment duration on prevalence of valve abnormalities","volume":"101","author":"Jollis","year":"2000","journal-title":"Circulation."},{"key":"key\n\t\t\t\t2019041106041248800_b107-0681791","volume-title":"Adipex-P (phentermine hydrochloride) package insert","year":"2005"},{"issue":"(suppl 2)","key":"key\n\t\t\t\t2019041106041248800_b108-0681791","first-page":"S109","article-title":"The role of 5-alpha reductase inhibitors in prostate pathophysiology: is there an additional advantage to inhibition of type 1 isoenzyme?","volume":"3","author":"Goldenberg","year":"2009","journal-title":"Can Urol Assoc J."},{"key":"key\n\t\t\t\t2019041106041248800_b109-0681791","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1056\/NEJMoa0908127","article-title":"Effect of dutasteride on the risk of prostate cancer","volume":"362","author":"Andriole","year":"2010","journal-title":"N Engl J Med."},{"key":"key\n\t\t\t\t2019041106041248800_b110-0681791","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/01.jcp.0000150217.51433.9f","article-title":"Adverse cardiac effects associated with clozapine","volume":"25","author":"Merrill","year":"2005","journal-title":"J Clin Psychopharmacol."},{"key":"key\n\t\t\t\t2019041106041248800_b111-0681791","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1016\/S0140-6736(99)10385-4","article-title":"Myocarditis and cardiomyopathy associated with clozapine","volume":"354","author":"Kilian","year":"1999","journal-title":"Lancet."},{"key":"key\n\t\t\t\t2019041106041248800_b112-0681791","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJM200107193450317","article-title":"Myocarditis and cardiomyopathy associated with clozapine use in the United States","volume":"345","author":"La Grenade","year":"2001","journal-title":"N Engl J Med."}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/68\/19\/1791\/28350224\/ajhp1791.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T01:05:14Z","timestamp":1712883914000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/68\/19\/1791\/5129429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,1]]},"references-count":112,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2011,10,1]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp100637","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2011,10,1]]},"published":{"date-parts":[[2011,10,1]]}}}